← All countries · Europe
91%
MCV1
2025 · WHO/UNICEF estimate
98%
DTP3
2025 · WHO/UNICEF estimate
98%
IPV complete
2025 · WHO/UNICEF estimate
98%
HepB3
2025 · WHO/UNICEF estimate
24
Measles cases
2025 reported
3
Pertussis (whooping cough) cases
2025 reported
Two kinds of number live on this page. Coverage is the share of the target cohort vaccinated, as estimated by WHO and UNICEF each July from the country's reports, surveys and other evidence, shown beside what the country itself reported. Reported cases are what the national surveillance system sent to WHO; they are a floor, not a count of infections. Every row carries a grade; hover or focus it for the reason, or read how grades are assigned.
Vaccination coverage
| Vaccine | Latest estimate | Country-reported | Trend since 2000 | Data quality |
|---|---|---|---|---|
| BCGTuberculosis vaccine at birth | —% · Administrative (country-reported) | — | too few points | no data |
| DTP1First dose of diphtheria-tetanus-pertussis | 99%2025 · WHO/UNICEF estimate | 100% | B · good | |
| DTP3Third dose of diphtheria-tetanus-pertussis (the WHO benchmark of a working programme) | 98%2025 · WHO/UNICEF estimate | 98.4% | B · good | |
| IPV1First dose of inactivated polio vaccine | 99%2025 · WHO/UNICEF estimate | 100% | B · good | |
| IPV completeInactivated polio vaccine, complete primary series | 98%2025 · WHO/UNICEF estimate | 98.4% | C · weak | |
| MCV1First dose of measles-containing vaccine | 91%2025 · WHO/UNICEF estimate | 90.9% | B · good | |
| MCV2Second dose of measles-containing vaccine | 98%2025 · WHO/UNICEF estimate | 97.8% | A · strong | |
| RCV1First dose of rubella-containing vaccine | 91%2025 · WHO/UNICEF estimate | 90.9% | A · strong | |
| HepB3Third dose of hepatitis B vaccine | 98%2025 · WHO/UNICEF estimate | 98.4% | B · good | |
| HepB birthHepatitis B birth dose within 24 hours | —% · Administrative (country-reported) | — | too few points | D · poor |
| Hib3Third dose of Haemophilus influenzae type b vaccine | 98%2025 · WHO/UNICEF estimate | 98.4% | B · good | |
| PCV1Pneumococcal conjugate vaccine, first dose | 91.3%2025 · Administrative (country-reported) | 91.3% | D · poor | |
| PCV completePneumococcal conjugate vaccine, final dose of the schedule | 83%2025 · WHO/UNICEF estimate | 83.0% | A · strong | |
| RotaCRotavirus vaccine, complete series | —% · Administrative (country-reported) | — | too few points | no data |
| Yellow feverYellow fever vaccine (countries at risk) | —% · Administrative (country-reported) | — | too few points | no data |
| MenAMeningococcal A conjugate (meningitis belt) | —% · Administrative (country-reported) | — | too few points | no data |
| JEJapanese encephalitis vaccine (countries at risk) | —% · Administrative (country-reported) | — | too few points | no data |
| TCVTyphoid conjugate vaccine | —% · Administrative (country-reported) | — | too few points | no data |
| PABProtection at birth against neonatal tetanus (maternal tetanus doses) | —% · Administrative (country-reported) | — | too few points | no data |
| HPV dose 1, girlsHPV programme coverage, first dose, girls | 71%2025 · WHO/UNICEF estimate | — | C · weak | |
| HPV complete, girlsHPV programme coverage, complete series, girls | 54%2025 · WHO/UNICEF estimate | — | C · weak | |
| HPV dose 1, boysHPV programme coverage, first dose, boys | 60%2025 · WHO/UNICEF estimate | — | D · poor |
Reported vaccine-preventable disease
| Disease | Reported cases | Incidence rate | Trend since 2000 | Data quality |
|---|---|---|---|---|
| Measles all countries · vaccine evidence | 242025 | 17.5per 1,000,000 total population | A · strong | |
| Rubella all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | A · strong | |
| Congenital rubella syndrome all countries · vaccine evidence | 02025 | 0per 10,000 live births | B · good | |
| Mumps all countries · vaccine evidence | 22025 | 1.5per 1,000,000 total population | A · strong | |
| Pertussis (whooping cough) all countries · vaccine evidence | 32025 | 2.2per 1,000,000 total population | A · strong | |
| Diphtheria all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | B · good | |
| Tetanus (total) all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | B · good | |
| Neonatal tetanus all countries · vaccine evidence | 02025 | 0per 1,000 live births | C · weak | |
| Polio (paralytic) all countries · vaccine evidence | 02022 | 0per 1,000,000 <15 population | D · poor | |
| Yellow fever all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | B · good | |
| Japanese encephalitis all countries · vaccine evidence | 02017 | 0per 1,000,000 total population | too few points | D · poor |
| Invasive meningococcal disease all countries · vaccine evidence | 102025 | 7.3per 1,000,000 total population | C · weak | |
| Typhoid all countries · vaccine evidence | 12025 | 0.7per 1,000,000 total population | B · good |
National schedule (latest WHO listing)
Show the schedule (55 rows)
| Vaccine | Dose | Age | Target group | Comment |
|---|---|---|---|---|
| BCGBCG (Baccille Calmette Guérin) vaccine | 1 | Risk group(s) | Persons with continuous contact with a contagious form of TB | |
| COVID19COVID-19 vaccine | 1 | Adults | All older adults | |
| DTAPHIBHEPBIPVDTaP-Hib-HepB-IPV (acellular) vaccine | 1 | M2-M3 | General/routine | |
| DTAPHIBHEPBIPVDTaP-Hib-HepB-IPV (acellular) vaccine | 2 | M4-M5 | General/routine | |
| DTAPHIBHEPBIPVDTaP-Hib-HepB-IPV (acellular) vaccine | 3 | M6-M8 | General/routine | |
| DTAPHIBIPVDTaP-Hib-IPV (acellular) vaccine | 4 | M18-M20 | General/routine | |
| DTAPIPVDTaP-IPV (acellular) vaccine | 5 | Y4-Y6 | General/routine | |
| HEPA_ADULTAdult Hepatitis A (HepA) vaccine | 1 | Risk group(s) | Special indications | |
| HEPA_PEDIATRICPediatric Hepatitis A (HepA) vaccine | 1 | M24 | General/routine | |
| HEPA_PEDIATRICPediatric Hepatitis A (HepA) vaccine | 2 | M30 | General/routine | |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 1 | Risk group(s) | Recommended for all people if not being vaccinated in childhood | |
| HEPB_PEDIATRICPediatric Hepatitis B (HepB) vaccine | 1 | B | Risk group(s) | children born to mothers with hepatitis B |
| HPV9HPV-9 (Human papillomavirus 9-valent) vaccine | 1 | Y9-Y13 | HPV administered to females and males | Both females and males |
| HPV9HPV-9 (Human papillomavirus 9-valent) vaccine | 2 | +M6 | HPV administered to females and males | Both females and males |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | >Y65 | Adults | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Health workers | Health and care workers | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Pregnant women | Pregnant women | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Risk group(s) | Adults with chronic conditions, residents living in long-term care facilities, other groups | |
| INFLUENZA_PEDIATRICPediatric seasonal influenza vaccine | 1 | M6-Y17 | General/routine | |
| INFLUENZA_PEDIATRICPediatric seasonal influenza vaccine | 1 | Risk group(s) | Children with chronic conditions | |
| IPVIPV (Inactivated polio vaccine) | 1 | Travellers | Booster dose for travellers where recommended | |
| MEN_ACYW_135CONJMeningococcal ACYW conjugate vaccine | 1 | M12 | General/routine | |
| MEN_ACYW_135CONJMeningococcal ACYW conjugate vaccine | 2 | Y11-Y12 | General/routine | |
| MMRMMR (Measles, mumps and rubella) vaccine | 1 | M12-M15 | General/routine | |
| MMRMMR (Measles, mumps and rubella) vaccine | 2 | Y3-Y6 | General/routine | |
| PCV10PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine | 1 | M3 | General/routine | |
| PCV10PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine | 2 | M5 | General/routine | |
| PCV10PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine | 3 | M12-M15 | General/routine | |
| PCV20PCV-20 (Pneumococcal conjugate vaccine 20-valent) vaccine | 1 | M2 | General/routine | |
| PCV20PCV-20 (Pneumococcal conjugate vaccine 20-valent) vaccine | 2 | M4 | General/routine | |
| PCV20PCV-20 (Pneumococcal conjugate vaccine 20-valent) vaccine | 3 | M6 | General/routine | |
| PCV20PCV-20 (Pneumococcal conjugate vaccine 20-valent) vaccine | 4 | M12-M15 | General/routine | |
| PCV_15_VALENTPCV-15 (Pneumococcal conjugate vaccine 15-valent) vaccine | 1 | M2 | General/routine | |
| PCV_15_VALENTPCV-15 (Pneumococcal conjugate vaccine 15-valent) vaccine | 2 | M4 | General/routine | |
| PCV_15_VALENTPCV-15 (Pneumococcal conjugate vaccine 15-valent) vaccine | 3 | M11-M15 | General/routine | |
| PPV23PPV-23 (Pneumococcal polysaccharide 23-valent) vaccine | 1 | Risk group(s) | high-risk groups | |
| RSVRSV (Respiratory syncytial virus) vaccine | 1 | >=Y75 | Adults | Individuals aged over 75 years |
| RSVRSV (Respiratory syncytial virus) vaccine | 1 | Pregnant women | Recommended for pregnant women aged ≥18 years, between 32 and 36 weeks of gestation | |
| RSVRSV (Respiratory syncytial virus) vaccine | 1 | Y60-Y74 | Risk group(s) | Individuals aged 60–74 years with risk factors (e.g. chronic cardiovascular disease or other underlying medical conditions) |
| RSV_MONORSV (Respiratory syncytial virus) monoclonal antibodies | 1 | Catch-up children | Infants younger than 8 months during their first RSV season who did not receive nirsevimab (Beyfortus) at birth. One single dose is recommended before the seasonal RSV surge. | |
| RSV_MONORSV (Respiratory syncytial virus) monoclonal antibodies | 1 | B | General/routine | Newborns born between October – March |
| RSV_MONORSV (Respiratory syncytial virus) monoclonal antibodies | 1 | Risk group(s) | High-risk infants and children aged 8–24 months entering their second RSV season, including premature infants (≤35 weeks gestation), children with chronic lung disease, congenital heart disease, severe immunosuppression, metabolic disorders, neuromuscular diseases, severe pulmonary diseases, genetic syndromes (e.g. Down syndrome), cystic fibrosis, and palliative care patients. | |
| TDAP_STdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine | 1 | Adults | Single dose in adults and for women in every pregnancy | |
| TDAP_STdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine | 1 | Pregnant women | Single dose in adults and for women in every pregnancy | |
| TDAP_STdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine | 6 | Y11-Y12 | General/routine | |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 1 | 1st contact | Adults | Adult booster doses every 10 years. Primary immunisation for people with unknown immunisation status, missing or incomplete primary vaccination. In persons with tetanus-prone injuries indicated in children over 5 years of age |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 1 | Risk group(s) | Adult booster doses every 10 years. Primary immunisation for people with unknown immunisation status, missing or incomplete primary vaccination. In persons with tetanus-prone injuries indicated in children over 5 years of age | |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 2 | +Y10 | Adults | Adult booster doses every 10 years. Primary immunisation for people with unknown immunisation status, missing or incomplete primary vaccination. In persons with tetanus-prone injuries indicated in children over 5 years of age |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 3 | +Y10 | Adults | Adult booster doses every 10 years. Primary immunisation for people with unknown immunisation status, missing or incomplete primary vaccination. In persons with tetanus-prone injuries indicated in children over 5 years of age |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 4 | +Y10 | Adults | Adult booster doses every 10 years. Primary immunisation for people with unknown immunisation status, missing or incomplete primary vaccination. In persons with tetanus-prone injuries indicated in children over 5 years of age |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 5 | +Y10 | Adults | Adult booster doses every 10 years. Primary immunisation for people with unknown immunisation status, missing or incomplete primary vaccination. In persons with tetanus-prone injuries indicated in children over 5 years of age |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 6 | +Y10 | Adults | Adult booster doses every 10 years. Primary immunisation for people with unknown immunisation status, missing or incomplete primary vaccination. In persons with tetanus-prone injuries indicated in children over 5 years of age |
| TYPHOID_PSTyphoid polysaccharide vaccine | 1 | Travellers | Travellers when indicated | |
| VARICELLAVaricella vaccine | 1 | M12-M15 | General/routine | |
| VARICELLAVaricella vaccine | 2 | Y4-Y6 | General/routine |
Compare schedules across 31 countries on the schedule hub.
Data and sources
- Download this country's data (JSON): every year, every antigen and disease, with the grade reasons.
- Coverage: WHO/UNICEF Estimates of National Immunization Coverage (WUENIC) and country-reported administrative/official coverage, from the WHO Immunization Data Portal export downloaded 21 October 2026.
- Reported cases and incidence: WHO/UNICEF Joint Reporting Form, same export. Incidence denominators are stated per row.
- Schedule: WHO vaccine-schedule export, latest listing year.